Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 14/20 | 0.56 |
| ▸ | AKT1 | P31749 | 14/20 | 0.56 |
| ▸ | AKT2 | P31751 | 9/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | PRKCB | P05771 | 2/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.45 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24085581 | 1.00 | AKT3 (0.56) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL22308123 | 0.88 | AKT3 (0.59) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL31628449 | 0.86 | AKT3 (0.61) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL2798957 | 0.86 | KIT (0.50) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL22288501 | 0.85 | AKT1 (0.58) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL28615754 | 0.83 | AKT3 (0.56) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL22308109 | 0.82 | AKT3 (0.57) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL29208220 | 0.82 | AKT3 (0.57) | AKT3AKT1AKT2CYP1A2CYP3A4 | |
| SCHEMBL192015 | 0.81 | KIT (0.48) | KIT | |
| SCHEMBL192014 | 0.81 | KIT (0.48) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115485276-A | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220144821-A1 | AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3919491-A1 | AKT INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021228223-A1 | DEUTERATED AKT KINASE INHIBITOR | 南京正大天晴制药有限公司 | 2021-11-18 | — | — | WO | disclosed |
| CN-113272304-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020156437-A1 | AKT INHIBITOR | 南京正大天晴制药有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144821-A1 | AKT INHIBITOR | AKT2, AKT1, MTOR | AKT3 4/4885AKT1 2/4885AKT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.